Table 1.
Characteristics of study subjects*
| RA subjects (n = 189) |
Non-RA controls (n = 189) |
P | |
|---|---|---|---|
| Demographics | |||
| Age, mean ± SD years | 59.9 ± 8.4 | 60.7 ± 8.8 | 0.367 |
| Women | 117 (61.9) | 117 (61.9) | 1.000 |
| White | 165 (87.3) | 165 (87.3) | 1.000 |
| Current smoker | 21 (11.1) | 4 (2.1) | < 0.001 |
| Postmenopausal women | 92 (78.6) | 91 (77.8) | 0.874 |
| RA disease characteristics | |||
| RA duration, median (IQR) years | 9 (5–17) | - | - |
| Rheumatoid factor seropositivity | 124 (65.5) | - | - |
| Swollen joint count (range 0–42), median (IQR) | 7 (3–11) | - | - |
| Tender joint count (range 0–44), median (IQR) | 6 (3–13) | - | - |
| DAS28 score, mean ± SD | 3.67 ± 1.07 | - | - |
| HAQ score (range 0–3), mean ± SD | 0.85 ± 0.75 | - | - |
| Any joint deformity/replacement/fusion | 132 (69.8) | - | - |
| Deformed and replaced joint count, median (IQR) | 2 (0–7) | - | - |
| C-reactive protein level, median (IQR) mg/liter | 2.78 (1.13–7.69) | - | - |
| Current RA therapeutics | |||
| Any nonbiologic DMARD use | 158 (84.0) | - | - |
| Any biologic DMARD use | 85 (45.0) | - | - |
| Combination biologic and nonbiologic DMARD use | 66 (34.9) | - | - |
| Glucocorticoid use | 83 (43.9) | - | - |
| No DMARD use | 12 (6.3) | - | - |
*
Values are the number (percentage) unless otherwise indicated. RA = rheumatoid arthritis; IQR = interquartile range; DAS28 = Disease Activity Score in 28 joints; HAQ = Health Assessment Questionnaire; DMARD = disease-modifying antirheumatic drug.